Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Universiteit Antwerpen
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05750043CT.gov Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan | — | Completed | — | — | — |
NCT03052998CT.gov Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy | — | Completed | — | — | — |
NCT03852303CT.gov Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy | — | Completed | — | — | — |
NCT05749653CT.gov Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ivermectin (this asset) | Universiteit Antwerpen | Approved | B · 62 |
| Topiramate | Université de Sherbrooke | P4 | BBB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P4 | BBB |
| Lacosamide | Second Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Neurotop | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Levetiracetam | Beijing Tiantan Hospital | P4 | BBB |
| Lamotrigine | Assiut University | P4 | BBB |
| Valproic Acid | Sanofi | P4 | BBB |
| Midazolam | Haseki Training and Research Hospital | P4 | BBB |
+42 more in the Epilepsy cohort
Other indications for Ivermectin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Onchocerciasis | — | P4 | BB · 64 |
| Breast Cancer | — | P1/2 | CC · 45 |
| Triple-Negative Breast Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ivermectin in Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ivermectin-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →